Study #2023-0261
A phase 1B/2A trial of NADUNOLIMAB in combination with Azacitidine (with/without Venetoclax) in patients with Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
MD Anderson Study Status
Enrolling
Treatment Agent
Nadunolimab, Azacitidine, Venetoclax
Description
To evaluate safety and determine the recommended Phase II dose (RP2D). We hypothesize that targeting leukemia stem/progenitor cells (LSCs) with nadunolimab (IL1RAP antibody) alone or in combination with current therapies of azacitidine (HMA) and venetoclax (Bcl-2 inhibitor), is an effective treatment strategy for high-risk MDS and AML, and with a clinical trial we will establish the safety and the early efficacy of this approach.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myelodysplastic Syndrome(MDS), Acute Myelogenous Leukemia (AML)
Study phase:
Physician name:
Gautam Borthakur
Department:
Leukemia
For general questions about clinical trials:
1-833-670-2212
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.